ELI-005 / Elicio Therap - LARVOL DELTA

Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. (PubMed, NPJ Vaccines) - "Here we evaluated an Amphiphile (AMP) adjuvant, AMP-CpG, admixed with SARS-CoV-2 Spike receptor binding domain (RBD) immunogen, as a lymph node-targeted protein subunit vaccine (ELI-005) in mice and non-human primates (NHPs). Expansion of RBD-specific germinal center (GC) B cells in lymph nodes correlated to rapid seroconversion with variant-specific neutralizing antibody responses exceeding those measured in convalescent human plasma. These results demonstrate the promise of lymph-node adjuvant-targeting to coordinate innate immunity and generate robust adaptive responses critical for vaccine efficacy."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. (PubMed, Sci Adv) - "Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice...Both cellular and humoral immune responses were preserved in aged mice. These advantages merit clinical translation to SARS-CoV-2 and other protein subunit vaccines."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases